OPKO Health, Inc.

OPK • Biotechnology

$1.64

▲ +0.03 (+1.86%)

Current price

EarningsLatest report: Jun 30, 2026

HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.

Market Cap

$1.24B

Growth

13.2%

Cash Flow

1/5

Trend

Volatile

Evidence

Manageable debt level · 0.34Healthy liquidity · 3.97Negative growth trendWeak profitability

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$1.64

Change1.86%

Shares Out757.06M

Market Cap$1.24B

Enterprise Value$1.10B

52W Range0.98 - 1.73

Beta1.48

P/E-17.03

P/S2.11

P/B1.05

P/FCF-9.26

EV/Sales1.88

Price$1.64

Change1.86%

Shares Out757.06M

Market Cap$1.24B

Enterprise Value$1.10B

52W Range0.98 - 1.73

Beta1.48

P/E-17.03

P/S2.11

P/B1.05

P/FCF-9.26

EV/Sales1.88

EV/EBITDA-13.37

EV/FCF-8.23

Earnings Yield-5.87%

FCF Yield-10.79%

Dividend Yield0.00%

Gross Margin21.10%

Oper. Margin-36.08%

Profit Margin-37.19%

Debt/Eq0.34

Current Ratio3.97

Quick Ratio3.52

Revenue 5Y13.19%

Target$2.87

Target Upside75.00%

Target Median$3.00

Target Range1.60 - 4.00

Volume3.20M

Avg Volume3.45M

EPS Surprise0.00

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

75/100

Growth Potential

Revenue and expansion

20/100

Price Attractiveness

Cheap or expensive today

93/100

Why this score▼

Manageable debt level · 0.34Healthy liquidity · 3.97Negative growth trendWeak profitability

Analyst view

Analyst sentiment and price target

OPK

Analyst sentiment

Based on 13 analyst votes · 2026-09-05

77/100

Bullish

Hold

Bearish

Price Target

2026-07-31

Low

$1.60

Mean

$2.87

Median

$3.00

High

$4.00

Company Overview

IPO: 11/2/1995

Industry: Biotechnology

P/B i: 1.05

Debt / Equity i: 0.34

Operating Margin: -36.08%

Net Margin: -37.19%

ROE i: -

ROIC: -

Financial Health

Score15 / 20

Debt / Equity: 0.34

Current Ratio: 3.97

Quick Ratio: 3.52

Status: Good

Insider Transactions

Recent executive and insider activity

⚠ 1 high-volume insider sell detected

Rubin Steven D

Transaction: 07/24/2026

SELL

Change

-53,266

Price

$1.22

Filing

07/28/2026

Type

SELL

Logal Adam

Transaction: 07/24/2026

SELL

Change

-53,266

Price

$1.22

Filing

07/28/2026

Type

SELL

Yu Alice Lin-Tsing

Transaction: 06/18/2026

BUY

Change

+30,000

Price

$1.42

Filing

06/22/2026

Type

BUY

Insider	Type	Change	Price	Transaction	Filing
Rubin Steven D	SELL	-53,266	$1.22	07/24/2026	07/28/2026
Logal Adam	SELL	-53,266	$1.22	07/24/2026	07/28/2026
Yu Alice Lin-Tsing	BUY	+30,000	$1.42	06/18/2026	06/22/2026
UPPALURI SUBBARAO V	BUY	+80,000	$1.42	06/18/2026	06/22/2026
PFENNIGER RICHARD C JR	BUY	+60,000	$1.42	06/18/2026	06/22/2026
PAGANELLI JOHN A	BUY	+30,000	$1.42	06/18/2026	06/22/2026
MEDEL ROGER MD	BUY	+30,000	$1.42	06/18/2026	06/22/2026
Lachman Prem A	BUY	+30,000	$1.42	06/18/2026	06/22/2026
PAGANELLI JOHN A	BUY	+10,000	$1.14	03/20/2026	03/20/2026
UPPALURI SUBBARAO V	OTHER	0	Not reported	03/18/2026	03/20/2026
UPPALURI SUBBARAO V	BUY	+50,000	$1.17	03/18/2026	03/20/2026
FROST PHILLIP MD ET AL	BUY	+102,371	$1.30	11/21/2025	11/21/2025
FROST PHILLIP MD ET AL	BUY	+119,129	$1.32	11/20/2025	11/20/2025
FROST PHILLIP MD ET AL	BUY	+36,325	$1.28	11/19/2025	11/19/2025
FROST PHILLIP MD ET AL	BUY	+410	$1.25	11/18/2025	11/18/2025
FROST PHILLIP MD ET AL	BUY	+150,000	$1.42	10/31/2025	10/31/2025
FROST PHILLIP MD ET AL	SELL	-440,000	Not reported	08/18/2025	08/19/2025
FROST PHILLIP MD ET AL	BUY	+675,000	$1.32	08/08/2025	08/08/2025
Nabel Gary J.	BUY	+437,500	$1.31	05/27/2025	05/29/2025
Logal Adam	BUY	+437,500	$1.31	05/27/2025	05/29/2025

About the Company

OPKO Health, Inc.

OPKO Health, Inc. operates as a healthcare enterprise with a dual focus on diagnostics and pharmaceuticals. Its operations span the United States, Ireland, Chile, Spain, Israel, Mexico, and other international markets. The company's Diagnostics division encompasses BioReference Laboratories, which delivers a comprehensive suite of laboratory testing services. These services are crucial for disease detection, diagnosis, evaluation, monitoring, and treatment, covering areas such as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare. BioReference serves a diverse client base, including medical practices, clinics, hospitals, employers, and government entities. Additionally, this segment provides a cutting-edge diagnostic instrument system designed for immediate, point-of-care blood test results, alongside its specialized 4Kscore testing for prostate cancer. Within the Pharmaceutical segment, OPKO offers a range of therapeutic products and a robust development pipeline. Key offerings include Rayaldee, indicated for the management of secondary hyperparathyroidism in adults suffering from stage 3 or 4 chronic kidney disease and vitamin D insufficiency. The pipeline features OPK88004, an investigational orally administered selective androgen receptor modulator; OPK88003, a peptide administered once weekly currently in Phase IIb trials for the treatment of type 2 diabetes and obesity; and hGH-CTP, a once-weekly human growth hormone injection that has successfully completed Phase III clinical trials in collaboration with Pfizer, Inc. A core strategy for this segment involves the development and commercialization of proprietary, extended-release versions of existing therapeutic proteins. Furthermore, OPKO Health supplies specialty active pharmaceutical ingredients (APIs) and is involved in the development, manufacturing, marketing, and sale of pharmaceutical, nutraceutical, veterinary, and ophthalmic products. The company also commercializes food supplements and over-the-counter products, produces and sells items primarily within the generics market, and handles the import, marketing, distribution, and sales of pharmaceutical products across various therapeutic areas, including cardiovascular conditions, vaccines, antibiotics, gastro-intestinal ailments, and hormone-related treatments, among others. Its pharmaceutical operations are further bolstered by platforms situated in Ireland, Chile, Spain, and Mexico. Founded in 1991, OPKO Health, Inc. maintains its corporate headquarters in Miami, Florida.

Source - link

Peers

CTEV DNTH LFMD NKTR OCS PCRX PSNL SANA TNDM XNCR

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Connor Clark & Lunn Investment Management Ltd. Invests $618,000 in OPKO Health, Inc. $OPK

Connor Clark and Lunn Investment Management Ltd. acquired a new stake in OPKO Health, Inc. (NASDAQ: OPK) in the quarter, according to the company in its most recent filing with the SEC. The fund acquired 412,051 shares of the biotechnology company's stock, valued at approximately $618,000. Connor Clark and Lunn Investment Management

Defense World

Why Is OPKO Health (OPK) Down 9.7% Since Last Earnings Report?

OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research

Here's Why You Should Retain OPK Stock in Your Portfolio for Now

OPKO Health's growth outlook is supported by RAYALDEE, strategic partnerships, BioReference restructuring and multiple pipeline catalysts.

Zacks Investment Research

OPK Raises $125 Million Against Royalties: What Investors Should Know

OPKO Health secured $125 million in royalty-backed financing, adding non-dilutive capital while retaining long-term exposure to mazdutide growth in China.

Zacks Investment Research

Is OPK Worth Buying as Valuation Meets Improving Business Trends?

OPKO Health pairs a discounted forward sales multiple with narrowing losses and partnership support, but early-stage clinical risk keeps the investment case balanced.

Zacks Investment Research

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-04-28	-0.07	-0.07	0
2026-02-26	-0.07	-0.04	0.03
2025-10-29	-0.02	0.03	0.05
2025-07-31	-0.12	-0.19	-0.07
2025-04-30	-0.06	-0.1	-0.04
2025-02-27	-0.08	0.01	0.09
2024-11-07	-0.1	0.03	0.13
2024-08-07	-0.09	-0.01	0.08
2024-05-07	-0.09	-0.12	-0.03
2024-02-27	-0.09	-0.09	0
2023-11-06	-0.09	-0.11	-0.02
2023-08-03	-0.07	-0.03	0.04